Suppr超能文献

过敏原免疫治疗欧洲过敏与临床免疫学会百年庆典:未解答问题的回顾。

One hundred years of allergen immunotherapy European Academy of Allergy and Clinical Immunology celebration: review of unanswered questions.

机构信息

Imperial College London, National Heart and Lung Institute, London, UK.

出版信息

Allergy. 2012 Apr;67(4):462-76. doi: 10.1111/j.1398-9995.2012.02785.x. Epub 2012 Feb 6.

Abstract

Allergen immunotherapy was introduced by Leonard Noon 100 years ago and is the only disease-modifying treatment for allergic individuals. Improved understanding of immunology has taught us a great deal about the underlying mechanisms involved in allergen immunotherapy; however, despite these developments, a number of important questions remain unanswered. Several of these questions relate to the practice of allergen immunotherapy in the clinic, such as: Is it possible to unify units of allergen potency? Which treatment schedules are best? Is allergen immunotherapy effective in all patient groups? Is there a dose-response relationship for efficacy and safety?, and Is there evidence for long-term effects following allergen immunotherapy? Others are related to new developments, such as new indications, or developments in the production of allergens. On the centenary of Noon's discovery, European experts in the field of immunotherapy met in Geneva under the aegis of the EAACI to discuss these controversial issues. This study presents outcomes and conclusions from these discussions.

摘要

过敏原免疫疗法由伦纳德·努恩(Leonard Noon)于 100 年前引入,是唯一可改变过敏性个体疾病进程的治疗方法。对免疫学的深入了解使我们深入了解了过敏原免疫疗法所涉及的潜在机制;然而,尽管有这些进展,仍有许多重要的问题尚未得到解答。其中一些问题与临床中的过敏原免疫疗法实践有关,例如:是否可以统一过敏原效价单位?哪种治疗方案最佳?过敏原免疫疗法对所有患者群体都有效吗?疗效和安全性是否存在剂量反应关系?过敏原免疫疗法是否有长期效果的证据?其他问题则与新的发展有关,如新的适应证或过敏原生产的发展。在努恩发现 100 周年之际,免疫治疗领域的欧洲专家在 EAACI 的支持下在日内瓦开会,讨论了这些有争议的问题。本研究介绍了这些讨论的结果和结论。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验